Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-antidepressant-switching-vs-augmentation-on-remission-among-czt0UOLRmu
References (28)
-
S. Mohamed, D. Leslie, R. Rosenheck (2009)
Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.The Journal of clinical psychiatry, 70 6
-
A. Rush, M. Trivedi, Hicham Ibrahim, T. Carmody, B. Arnow, D. Klein, J. Markowitz, P. Ninan, S. Kornstein, R. Manber, M. Thase, J. Kocsis, M. Keller (2003)
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionBiological Psychiatry, 54
-
(1976)
ECDEU Assessment Manual for Psychopharmacology -
J. Israel (2006)
Remission in depression: definition and initial treatment approachesJournal of Psychopharmacology, 20
-
S. Zisook, Ilanit Tal, K. Weingart, P. Hicks, L. Davis, Peijun Chen, Jean Yoon, Gary Johnson, J. Vertrees, Sanjai Rao, Patricia Pilkinton, J. Wilcox, M. Sapra, A. Iranmanesh, Grant Huang, S. Mohamed (2016)
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report.Journal of affective disorders, 206
-
A Sharper Bonferroni Procedure for Multiple Tests of Significance -
Changsu Han, Sheng-Min Wang, K. Kwak, W. Won, Hwayoung Lee, Chia-Ming Chang, T. Tang, C. Pae (2015)
Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.Journal of psychiatric research, 66-67
-
S. Mohamed, Gary Johnson, J. Vertrees, P. Guarino, K. Weingart, I. Young, Jean Yoon, T. Gleason, Katherine Kirkwood, A. Kilbourne, M. Gerrity, Stephen Marder, Kousick Biswas, P. Hicks, L. Davis, Peijun Chen, Alexandra Kelada, Grant Huang, David Lawrence, Mary LeGwin, S. Zisook (2015)
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerationsPsychiatry Research, 229
-
R. Sansone, L. Sansone (2012)
Antidepressant adherence: are patients taking their medications?Innovations in clinical neuroscience, 9 5-6
-
J. Lieberman, T. Stroup, J. McEvoy, J. McEvoy, M. Swartz, R. Rosenheck, D. Perkins, R. Keefe, S. Davis, C. Davis, B. Lebowitz, J. Severe, J. Hsiao (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, 353 12
-
M. Trivedi, M. Fava, S. Wisniewski, M. Thase, F. Quitkin, D. Warden, Louise Ritz, A. Nierenberg, Barry Lebowitz, M. Biggs, J. Luther, K. Shores‐Wilson, A. Rush (2006)
Medication augmentation after the failure of SSRIs for depression.The New England journal of medicine, 354 12
-
K. Kroenke, R. Spitzer, Janet Williams (2001)
The PHQ-9Journal of General Internal Medicine, 16
-
S. Wisniewski, A. Rush, G. Balasubramani, M. Trivedi, A. Nierenberg (2006)
Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side EffectsJournal of Psychiatric Practice, 12
-
S. Kolovos, M. Tulder, P. Cuijpers, A. Prigent, K. Chevreul, H. Riper, J. Bosmans (2017)
The effect of treatment as usual on major depressive disorder: A meta-analysis.Journal of affective disorders, 210
-
J. Rush, J. Rush, D. Warden, S. Wisniewski, Maurizio Fava, M. Trivedi, B. Gaynes, A. Nierenberg (2009)
STAR*DCNS Drugs, 23
-
A. Rush, M. Trivedi, S. Wisniewski, J. Stewart, A. Nierenberg, M. Thase, Louise Ritz, M. Biggs, D. Warden, J. Luther, K. Shores‐Wilson, G. Niederehe, M. Fava (2006)
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.The New England journal of medicine, 354 12
-
A. Rush, M. Trivedi, S. Wisniewski, A. Nierenberg, J. Stewart, D. Warden, G. Niederehe, M. Thase, P. Lavori, B. Lebowitz, P. McGrath, J. Rosenbaum, H. Sackeim, D. Kupfer, J. Luther, M. Fava (2006)
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 163
-
(2000)
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.The American journal of psychiatry, 157 4 Suppl
-
M. Trivedi (2009)
Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission.The Journal of clinical psychiatry, 70 Suppl 6
-
G. Boehm, J. Racoosin, T. Laughren, R. Katz (2004)
Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.Diabetes care, 27 8
-
J. Goldberg, M. Freeman, R. Balon, L. Citrome, M. Thase, J. Kane, M. Fava (2015)
THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERSDepression and Anxiety, 32
-
B. Arbaizar, T. Dierssen-Sotos, I. Gómez-Acebo, J. Llorca (2009)
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials.General hospital psychiatry, 31 5
-
S. Kennedy, R. Lam, R. McIntyre, S. Tourjman, Venkat Bhat, P. Blier, M. Hasnain, F. Jollant, A. Levitt, G. MacQueen, S. McInerney, D. Mcintosh, R. Milev, Daniel Müller, S. Parikh, Norma Pearson, A. Ravindran, R. Uher (2016)
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive DisorderThe Canadian Journal of Psychiatry, 61
-
C. Murray, C. Atkinson, K. Bhalla, G. Birbeck, R. Burstein, David Chou, R. Dellavalle, G. Danaei, M. Ezzati, A. Fahimi, D. Flaxman, Foreman, S. Gabriel, E. Gakidou, N. Kassebaum, S. Khatibzadeh, S. Lim, S. Lipshultz, S. London, López, Michael MacIntyre, A. Mokdad, A. Moran, Andrew Moran, D. Mozaffarian, Tasha Murphy, M. Naghavi, C. Pope, Thomas Roberts, J. Salomon, D. Schwebel, S. Shahraz, D. Sleet, Murray, J. Abraham, Mohammed Ali, D. Bartels, Honglei Chen, M. Criqui, Dahodwala, Jarlais, E. Ding, E. Dorsey, B. Ebel, Fahami, S. Flaxman, A. Flaxman, D. González-Medina, B. Grant, H. Hagan, H. Hoffman, J. Leasher, J. Lin, R. Lozano, Yuan Lu, Leslie Mallinger, M. McDermott, R. Micha, T. Miller, A. Mokdad, M. Naghavi, K. Narayan, S. Omer, P. Pelizzari, D. Phillips, D. Ranganathan, F. Rivara, Uchechukwu Sampson, Ella Sanman, A. Sapkota, Saeid Sharaz, R. Shivakoti, Gitanjali Singh, David Singh, M. Tavakkoli, J. Towbin, J. Wilkinson, A. Zabetian, Mohammad Ali, M. Alvardo, L. Baddour, E. Benjamin, I. Bolliger, Emily Carnahan, S. Chugh, A. Cohen, K. Colson, L. Cooper, W. Couser, Kaustubh Dabhadkar, R. Dellavalle, D. Dicker, H. Duber, Rebecca Engell, David Felson, M. Finucane, S. Flaxman, T. Fleming, M. Forouzanfar, Greg Freedman, Michael Freeman, R. Gillum, R. Gosselin, H. Gutierrez, Rasmus Havmoeller, K. Jacobsen, S. James, Rashmi Jasrasaria, Sudha Jayarman, N. Johns, Q. Lan, M. Meltzer, G. Mensah, C. Michaud, C. Mock, T. Moffitt, R. Nelson, Casey Olives, K. Ortblad, B. Ostro, M. Raju, H. Razavi, B. Ritz, R. Sacco, K. Shibuya, D. Silberberg, J. Singh, K. Steenland, Jennifer Taylor, G. Thurston, M. Vavilala, T. Vos, G. Wagner, M. Weinstock, M. Weisskopf, S. Wulf (2013)
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.JAMA, 310 6
-
Jared Adams, R. Drake (2006)
Shared Decision-Making and Evidence-Based PracticeCommunity Mental Health Journal, 42
-
A. Cleare, C. Pariante, A. Young, I. Anderson, D. Christmas, P. Cowen, C. Dickens, I. Ferrier, J. Geddes, S. Gilbody, P. Haddad, C. Katona, G. Lewis, A. Malizia, R. McAllister-Williams, P. Ramchandani, Jan Scott, David Taylor, R. Uher (2015)
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelinesJournal of Psychopharmacology, 29
-
M. Fava, A. Rush, J. Alpert, G. Balasubramani, S. Wisniewski, C. Carmin, M. Biggs, S. Zisook, A. Leuchter, R. Howland, D. Warden, M. Trivedi (2008)
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.The American journal of psychiatry, 165 3
-
J. Levine, N. Schooler (1986)
SAFTEE: a technique for the systematic assessment of side effects in clinical trials.Psychopharmacology bulletin, 22 2
- Publisher
- American Medical Association
- Copyright
- Copyright 2017 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2017.8036
- pmid
- 28697253
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionIs there a difference among pharmacotherapeutic approaches for treating patients with depression unresponsive to an antidepressant course? FindingsIn a 12-week follow-up of a randomized clinical trial of 1522 patients with major depressive disorder (85% men) unresponsive to previous antidepressant treatment, 29% achieved remission after augmenting their antidepressant with the antipsychotic aripiprazole vs 22% who switched to the antidepressant bupropion. Other remission comparisons were not significant. MeaningAugmentation with aripiprazole resulted in a statistically significant, but only modestly increased, likelihood of remission during 12 weeks of treatment compared with switching to bupropion alone.
Journal
JAMA – American Medical Association
Published: Jul 11, 2017